Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Метаболический синдром и метаболически здоровое ожирение у молодых мужчин
Метаболический синдром и метаболически здоровое ожирение у молодых мужчин
Гончарова Е.В., Петунина Н.А., Бокерия О.Л., Архипкин А.А. Метаболический синдром и метаболически здоровое ожирение у молодых мужчин. Consilium Medicum. 2016; 18 (8): 64–67. DOI: 10.26442/2075-1753_2016.8.64-67
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В ходе ретроспективного и поперечного исследования оценена распространенность метаболического синдрома и метаболически здорового ожирения у молодых мужчин с дебютом ожирения с подросткового периода. Наблюдалось значительное сокращение фенотипа метаболически здорового ожирения при сравнении с подростковым периодом, а также с учетом дополнительных субклинических факторов риска: индекса HOMA-IR и высокочувствительного C-реактивного белка.
Ключевые слова: метаболический синдром, метаболически здоровое ожирение, молодые мужчины, индекс LAP, ожирение.
Ключевые слова: метаболический синдром, метаболически здоровое ожирение, молодые мужчины, индекс LAP, ожирение.
________________________________________________
A retrospective and cross-sectional study evaluated the prevalence of metabolic syndrome and metabolically healthy obesity in young men with obesity debut with adolescence. There was a significant reduction in the phenotype of the metabolically healthy obese when compared to adolescence, as well as taking into account additional risk factors for subclinical: HOMA-IR index, and high-sensitivity C-reactive protein.
Key words: metabolic syndrome, metabolically healthy obese young men, the LAP index, obesity.
Key words: metabolic syndrome, metabolically healthy obese young men, the LAP index, obesity.
Полный текст
Список литературы
1. World Health Organization Media Centre. Obesity and overweight. Fact sheet no 311: World Health Organization; 2015. http://www.who.int/mediacentre/factsheets/fs311/ru/
2. Garvey WT, Mechanick JI, Brett EM et al. AACE/ACE guidelines. American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for comprehensive medical care of patients with obesity – executive summary. Endocr Pract 2016. DOI: 10.4158/EP161365.GL
3. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome. A new worldwide definition. Metabolic syndrome – a new world-wide definition. Diabet Med 2006; 23 (5): 469–80. http://onlinelibrary.wiley.com/enhanced/doi/10.1111/j.1464-5491.2006.01858.x
4. Alberti KG, Eckel RH, Grundy SM et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120 (16): 1640–5. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192644 http://circ.ahajournals.org/content/120/16/1640.long
5. Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocr Metab Disord 2013; 14 (3): 219–27.
6. Clinical Guidelines on the identification, evaluation and treatment of overweight andobesity in adults. National Heart, Lung and Blood Institute, NIH 1998. https://www.nhlbi.nih.gov/files/docs/guidelines/ob_gdlns.pdf
7. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499 511. http://circ.ahajournals.org/content/circulationaha/107/3/499.full.pdf
8. Kahn H. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 2005; 5 (1): 26. DOI: 10,1186 / 1471-2261-5-26. http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC1236917/
2. Garvey WT, Mechanick JI, Brett EM et al. AACE/ACE guidelines. American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for comprehensive medical care of patients with obesity – executive summary. Endocr Pract 2016. DOI: 10.4158/EP161365.GL
3. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome. A new worldwide definition. Metabolic syndrome – a new world-wide definition. Diabet Med 2006; 23 (5): 469–80. http://onlinelibrary.wiley.com/enhanced/doi/10.1111/j.1464-5491.2006.01858.x
4. Alberti KG, Eckel RH, Grundy SM et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120 (16): 1640–5. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192644 http://circ.ahajournals.org/content/120/16/1640.long
5. Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocr Metab Disord 2013; 14 (3): 219–27.
6. Clinical Guidelines on the identification, evaluation and treatment of overweight andobesity in adults. National Heart, Lung and Blood Institute, NIH 1998. https://www.nhlbi.nih.gov/files/docs/guidelines/ob_gdlns.pdf
7. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499 511. http://circ.ahajournals.org/content/circulationaha/107/3/499.full.pdf
8. Kahn H. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 2005; 5 (1): 26. DOI: 10,1186 / 1471-2261-5-26. http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC1236917/
2. Garvey WT, Mechanick JI, Brett EM et al. AACE/ACE guidelines. American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for comprehensive medical care of patients with obesity – executive summary. Endocr Pract 2016. DOI: 10.4158/EP161365.GL
3. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome. A new worldwide definition. Metabolic syndrome – a new world-wide definition. Diabet Med 2006; 23 (5): 469–80. http://onlinelibrary.wiley.com/enhanced/doi/10.1111/j.1464-5491.2006.01858.x
4. Alberti KG, Eckel RH, Grundy SM et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120 (16): 1640–5. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192644 http://circ.ahajournals.org/content/120/16/1640.long
5. Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocr Metab Disord 2013; 14 (3): 219–27.
6. Clinical Guidelines on the identification, evaluation and treatment of overweight andobesity in adults. National Heart, Lung and Blood Institute, NIH 1998. https://www.nhlbi.nih.gov/files/docs/guidelines/ob_gdlns.pdf
7. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499 511. http://circ.ahajournals.org/content/circulationaha/107/3/499.full.pdf
8. Kahn H. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 2005; 5 (1): 26. DOI: 10,1186 / 1471-2261-5-26. http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC1236917/
________________________________________________
2. Garvey WT, Mechanick JI, Brett EM et al. AACE/ACE guidelines. American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for comprehensive medical care of patients with obesity – executive summary. Endocr Pract 2016. DOI: 10.4158/EP161365.GL
3. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome. A new worldwide definition. Metabolic syndrome – a new world-wide definition. Diabet Med 2006; 23 (5): 469–80. http://onlinelibrary.wiley.com/enhanced/doi/10.1111/j.1464-5491.2006.01858.x
4. Alberti KG, Eckel RH, Grundy SM et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120 (16): 1640–5. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192644 http://circ.ahajournals.org/content/120/16/1640.long
5. Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocr Metab Disord 2013; 14 (3): 219–27.
6. Clinical Guidelines on the identification, evaluation and treatment of overweight andobesity in adults. National Heart, Lung and Blood Institute, NIH 1998. https://www.nhlbi.nih.gov/files/docs/guidelines/ob_gdlns.pdf
7. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499 511. http://circ.ahajournals.org/content/circulationaha/107/3/499.full.pdf
8. Kahn H. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 2005; 5 (1): 26. DOI: 10,1186 / 1471-2261-5-26. http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC1236917/
Авторы
Е.В.Гончарова*1, Н.А.Петунина1, О.Л.Бокерия2, А.А.Архипкин3
1 ГБОУ ВПО Первый Московский государственный университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2 ФГБНУ Научный центр сердечно-сосудистой хирургии им. А.Н.Бакулева. 119049, Россия, Москва, Ленинский пр-т, 8;
3 ООО «Научный центр ЭФиС». 105062, Россия, Москва, ул. Садовая-Черногрязская, д. 16–18.
*goncharova_ev@list.ru
1 ГБОУ ВПО Первый Московский государственный университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2 ФГБНУ Научный центр сердечно-сосудистой хирургии им. А.Н.Бакулева. 119049, Россия, Москва, Ленинский пр-т, 8;
3 ООО «Научный центр ЭФиС». 105062, Россия, Москва, ул. Садовая-Черногрязская, д. 16–18.
*goncharova_ev@list.ru
________________________________________________
E.V.Goncharova*1, N.A.Petunina1, O.L.Bokeriia2, A.A.Arkhipkin3
1 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2 A.N.Bakulev Scientific Centre of Cardiovascular Surgery. 119049, Russian Federation, Moscow, Leninskii pr-t, 8;
3 Science Center EFiS. 105062, Russian Federation, Moscow, ul. Sadovaia-Chernogriazskaia, d. 16–18.
*goncharova_ev@list.ru
1 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2 A.N.Bakulev Scientific Centre of Cardiovascular Surgery. 119049, Russian Federation, Moscow, Leninskii pr-t, 8;
3 Science Center EFiS. 105062, Russian Federation, Moscow, ul. Sadovaia-Chernogriazskaia, d. 16–18.
*goncharova_ev@list.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.